IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
| Revenue (TTM) | $16.63B |
| Gross Profit (TTM) | $5.49B |
| EBITDA | $3.00B |
| Operating Margin | 13.60% |
| Return on Equity | 22.50% |
| Return on Assets | 5.13% |
| Revenue/Share (TTM) | $97.79 |
| Book Value | $38.34 |
| Price-to-Book | 4.50 |
| Price-to-Sales (TTM) | 1.69 |
| EV/Revenue | 2.524 |
| EV/EBITDA | 11.93 |
| Quarterly Earnings Growth (YoY) | 15.00% |
| Quarterly Revenue Growth (YoY) | 8.40% |
| Shares Outstanding | $166.90M |
| Float | $158.55M |
| % Insiders | 1.08% |
| % Institutions | 102.35% |
Volatility is currently contracting